BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 23793881)

  • 1. Difference in neointimal coverage at chronic stage between bare metal stent and sirolimus-eluting stent evaluated at stent-strut level by optical coherence tomography.
    Ikuta S; Kobuke K; Iwanaga Y; Nakauchi Y; Yamaji K; Miyazaki S
    Heart Vessels; 2014 May; 29(3):320-7. PubMed ID: 23793881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stent coverage and neointimal proliferation in bare metal stents postdilated with a Paclitaxel-eluting balloon versus everolimus-eluting stents: prospective randomized study using optical coherence tomography at 6-month follow-up.
    Poerner TC; Otto S; Gassdorf J; Nitsche K; Janiak F; Scheller B; Goebel B; Jung C; Figulla HR
    Circ Cardiovasc Interv; 2014 Dec; 7(6):760-7. PubMed ID: 25371536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optical coherence tomographic comparison of neointimal coverage between sirolimus- and resolute zotarolimus-eluting stents at 9 months after stent implantation.
    Kim JS; Kim JS; Shin DH; Kim BK; Ko YG; Choi D; Jang Y; Hong MK
    Int J Cardiovasc Imaging; 2012 Aug; 28(6):1281-7. PubMed ID: 21858655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Favorable neointimal coverage in everolimus-eluting stent at 9 months after stent implantation: comparison with sirolimus-eluting stent using optical coherence tomography.
    Choi HH; Kim JS; Yoon DH; Hong KS; Kim TH; Kim BK; Ko YG; Choi D; Jang Y; Hong MK
    Int J Cardiovasc Imaging; 2012 Mar; 28(3):491-7. PubMed ID: 21442265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neointimal coverage of zotarolimus-eluting stent at 1, 2, and 3 months' follow-up: an optical coherence tomography study.
    Hashikata T; Tojo T; Namba S; Kitasato L; Hashimoto T; Kameda R; Shimohama T; Yamaoka-Tojo M; Ako J
    Heart Vessels; 2016 Feb; 31(2):206-11. PubMed ID: 25362579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial findings of impact of strut width on stent coverage and apposition of sirolimus-eluting stents assessed by optical coherence tomography.
    Nakatani S; Nishino M; Taniike M; Makino N; Kato H; Egami Y; Shutta R; Tanouchi J; Yamada Y
    Catheter Cardiovasc Interv; 2013 Apr; 81(5):776-81. PubMed ID: 22517601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optical coherence tomography assessment of in vivo vascular response after implantation of overlapping bare-metal and drug-eluting stents.
    Guagliumi G; Musumeci G; Sirbu V; Bezerra HG; Suzuki N; Fiocca L; Matiashvili A; Lortkipanidze N; Trivisonno A; Valsecchi O; Biondi-Zoccai G; Costa MA;
    JACC Cardiovasc Interv; 2010 May; 3(5):531-9. PubMed ID: 20488410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of long-term follow-up with neointimal coverage and stent apposition after sirolimus-eluting stent implantation by optical coherence tomography.
    Li S; Gai L; Yang T; Zhang L; Xu X; Bai Q; Xu H; Wang Y
    Catheter Cardiovasc Interv; 2013 Apr; 81(5):768-75. PubMed ID: 22639418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Very long-term follow-up of strut apposition and tissue coverage with Biolimus A9 stents analyzed by optical coherence tomography.
    Staico R; Costa MA; Chamié D; Bezerra H; Armaganijan LV; Costa RA; Costa JR; Siqueira D; Centemero M; Chaves Á; Tanajura LF; Abizaid A; Feres F; Sousa JE; Sousa AG
    Int J Cardiovasc Imaging; 2013 Jun; 29(5):977-88. PubMed ID: 23456358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative and qualitative changes in DES-related neointimal tissue based on serial OCT.
    Kim JS; Hong MK; Shin DH; Kim BK; Ko YG; Choi D; Jang Y
    JACC Cardiovasc Imaging; 2012 Nov; 5(11):1147-55. PubMed ID: 23153915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serial assessment of vessel interactions after drug-eluting stent implantation in unprotected distal left main coronary artery disease using frequency-domain optical coherence tomography.
    Fujino Y; Attizzani GF; Bezerra HG; Wang W; Tahara S; Yamamoto H; Chamie D; Kanaya T; Mehanna E; Takagi K; Nakamura S; Costa MA
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1035-45. PubMed ID: 24156964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strut coverage and vessel wall response to zotarolimus-eluting and bare-metal stents implanted in patients with ST-segment elevation myocardial infarction: the OCTAMI (Optical Coherence Tomography in Acute Myocardial Infarction) Study.
    Guagliumi G; Sirbu V; Bezerra H; Biondi-Zoccai G; Fiocca L; Musumeci G; Matiashvili A; Lortkipanidze N; Tahara S; Valsecchi O; Costa M
    JACC Cardiovasc Interv; 2010 Jun; 3(6):680-7. PubMed ID: 20630463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of vascular responses after different types of second-generation drug-eluting stents implantation detected by optical coherence tomography.
    Ohtani H; Kimura S; Sugiyama T; Hishikari K; Misawa T; Mizusawa M; Hayasaka K; Yamakami Y; Kojima K; Sagawa Y; Hikita H; Ashikaga T; Takahashi A; Isobe M
    Int J Cardiovasc Imaging; 2017 Feb; 33(2):177-186. PubMed ID: 27761750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Very early tissue coverage after drug-eluting stent implantation: an optical coherence tomography study.
    Takahara M; Kitahara H; Nishi T; Miura K; Miyayama T; Sugimoto K; Nakayama T; Fujimoto Y; Kobayashi Y
    Int J Cardiovasc Imaging; 2017 Jan; 33(1):25-30. PubMed ID: 27601229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue coverage of paclitaxel and sirolimus eluting stents in long term follow-up: optical coherence tomography study.
    Kochman J; Pietrasik A; Rdzanek A; Ścibisz A; Pawlak M; Filipiak KJ; Opolski G
    Cardiol J; 2013; 20(3):247-53. PubMed ID: 23788298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective randomised study using optical coherence tomography to assess endothelial coverage and neointimal proliferation at 6-months after implantation of a coronary everolimus-eluting stent compared with a bare metal stent postdilated with a paclitaxel-eluting balloon (OCTOPUS Trial): rationale, design and methods.
    Poerner TC; Otto S; Gassdorf J; Janiak F; Danzer C; Ferrari M; Figulla HR
    EuroIntervention; 2011 May; 7 Suppl K():K93-9. PubMed ID: 22027737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neointimal coverage of bare-metal and sirolimus-eluting stents evaluated with optical coherence tomography.
    Chen BX; Ma FY; Luo W; Ruan JH; Xie WL; Zhao XZ; Sun SH; Guo XM; Wang F; Tian T; Chu XW
    Heart; 2008 May; 94(5):566-70. PubMed ID: 17923466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early vascular healing with rapid breakdown biodegradable polymer sirolimus-eluting versus durable polymer everolimus-eluting stents assessed by optical coherence tomography.
    Tada T; Byrne RA; Schuster T; Cuni R; Kitabata H; Tiroch K; Dirninger A; Gratze F; Kaspar K; Zenker G; Joner M; Schömig A; Kastrati A
    Cardiovasc Revasc Med; 2013; 14(2):84-9. PubMed ID: 23352095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neointimal coverage and vasodilator response to titanium-nitride-oxide-coated bioactive stents and everolimus-eluting stents in patients with acute coronary syndrome: insights from the BASE-ACS trial.
    Karjalainen P; Kiviniemi TO; Lehtinen T; Nammas W; Ylitalo A; Saraste A; Mikkelsson J; Pietila M; Biancari F; Airaksinen JK
    Int J Cardiovasc Imaging; 2013 Dec; 29(8):1693-703. PubMed ID: 23996244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A serial 3- and 9-year optical coherence tomography assessment of vascular healing response to sirolimus- and paclitaxel-eluting stents.
    Tomaniak M; Kołtowski Ł; Pietrasik A; Rdzanek A; Jąkała J; Proniewska K; Malinowski K; Mazurek T; Filipiak KJ; Brugaletta S; Opolski G; Kochman J
    Int J Cardiovasc Imaging; 2019 Jan; 35(1):9-21. PubMed ID: 30168010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.